UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neurodegenerative Disease and the NLRP3 Inflammasome

Frontiers in pharmacology, 2021-03, Vol.12, p.643254

2021

Volltextzugriff (PDF)

Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB) - a cross sectional study

Clinical nutrition (Edinburgh, Scotland), 2021-09, Vol.40 (9), p.5162-5168

2021

Volltextzugriff (PDF)

The burgeoning field of innate immune‐mediated disease and autoinflammation

The Journal of pathology, 2017-01, Vol.241 (2), p.123-139

2017

Volltextzugriff (PDF)

Aberrant mitochondrial homeostasis at the crossroad of musculoskeletal ageing and non-small cell lung cancer

PloS one, 2022-09, Vol.17 (9), p.e0273766-e0273766

2022

Volltextzugriff (PDF)

ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis

eLife, 2019-09, Vol.8

2019

Volltextzugriff (PDF)

Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis

eLife, 2020-03, Vol.9

2020

Volltextzugriff (PDF)

Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection

The New England journal of medicine, 2011-08, Vol.365 (6), p.518-526

2011

Volltextzugriff (PDF)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del

PloS one, 2024-05, Vol.19 (5), p.e0304555

2024

Volltextzugriff (PDF)

Butyrate regulates neutrophil homeostasis and impairs early antimicrobial activity in the lung

Mucosal immunology, 2023-08, Vol.16 (4), p.476-485

2023

Volltextzugriff (PDF)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Frontiers in pharmacology, 2022-06, Vol.13, p.877118

2022

Volltextzugriff (PDF)

Assessing arthritis in the context of cystic fibrosis

Pediatric pulmonology, 2019-06, Vol.54 (6), p.770-777

2019

Volltextzugriff (PDF)

Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

Journal of cystic fibrosis, 2021-09, Vol.20 (5), p.e46-e52

2021

Volltextzugriff (PDF)

Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation

Frontiers in immunology, 2019, Vol.10, p.1789-1789

2019

Volltextzugriff (PDF)

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

PloS one, 2020-12, Vol.15 (12), p.e0242945

2020

Volltextzugriff (PDF)

Survival of Mycobacterium abscessus isolated from people with cystic fibrosis in artificially generated aerosols

The European respiratory journal, 2016-12, Vol.48 (6), p.1789-1791

2016

Volltextzugriff (PDF)

Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia

The European respiratory journal, 2021-10, Vol.58 (4), p.2000455

2021

Volltextzugriff (PDF)

Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis

ERJ open research, 2022-04, Vol.8 (2), p.669

2022

Volltextzugriff (PDF)

β-lactam hypersensitivity involves expansion of circulating and skin-resident Th22 cells

Journal of allergy and clinical immunology, 2018-01, Vol.141 (1), p.235-249.e8

2018

Volltextzugriff (PDF)

Noninvasive Ventilation in Cystic Fibrosis: Clinical Indications and Outcomes in a Large UK Adult Cystic Fibrosis Center

Respiratory care, 2021-03, Vol.66 (3), p.466-474

2021

Volltextzugriff (PDF)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Frontiers in pharmacology, 2023-05, Vol.14, p.1207356-1207356

2023

Volltextzugriff (PDF)

Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis

The European respiratory journal, 2015-06, Vol.45 (6), p.1748-1751

2015

Volltextzugriff (PDF)

Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era

Current opinion in pulmonary medicine, 2022-11, Vol.28 (6), p.577-583

2022

Volltextzugriff (PDF)

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

BMJ open respiratory research, 2024-05, Vol.11 (1), p.e002049

2024

Volltextzugriff (PDF)

Hydrocephalus and diffuse choroid plexus hyperplasia in primary ciliary dyskinesia-related MCIDAS mutation

Neurology. Genetics, 2020-08, Vol.6 (4)

2020

Volltextzugriff (PDF)

Time to change course and tackle CF related obesity

Journal of cystic fibrosis, 2022-09, Vol.21 (5), p.732-734

2022

Volltextzugriff (PDF)

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(197)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neurodegenerative Disease and the NLRP3 Inflammasome

Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB) - a cross sectional study

The burgeoning field of innate immune‐mediated disease and autoinflammation

Aberrant mitochondrial homeostasis at the crossroad of musculoskeletal ageing and non-small cell lung cancer

ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis

Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis

Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del

Butyrate regulates neutrophil homeostasis and impairs early antimicrobial activity in the lung

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Assessing arthritis in the context of cystic fibrosis

Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

Survival of Mycobacterium abscessus isolated from people with cystic fibrosis in artificially generated aerosols

Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia

Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis

β-lactam hypersensitivity involves expansion of circulating and skin-resident Th22 cells

Noninvasive Ventilation in Cystic Fibrosis: Clinical Indications and Outcomes in a Large UK Adult Cystic Fibrosis Center

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis

Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

Hydrocephalus and diffuse choroid plexus hyperplasia in primary ciliary dyskinesia-related MCIDAS mutation

Time to change course and tackle CF related obesity

Suchergebnisse filtern